Abstract
The pharmaceutical industry in Croatia is relatively small and is dominated by
local and regional generic suppliers. The government is aiming to bring the
performance of the health sector into line with that of other EU member
states, through the National Health Strategy 2006-2011. This report is ideal
for executives wanting to understand the key drivers in the pharmaceutical
market and have access to a wealth of statistical data, including five-year
market projections. Included with the report are 3 free quarterly updated
outlook reports, enabling you to keep up to date with market developments for
a year.
Includes 3 quarterly updated outlook reports!
Once a prosperous part of Yugoslavia, Croatia' s infrastructure was decimated
by the civil war of the early 1990s. With the loss of income from its
lucrative industries and a sizeable refugee problem, the economy,
unsurprisingly, collapsed. In the years following the end of the conflict,
government reforms succeeded in producing modest levels of economic growth,
with international aid playing an important part in Croatia' s recovery,
funding the reconstruction of the country' s shattered infrastructure. In 1998,
however, the country experienced economic recession in the wake of the Asian
and Russian crises, which led to severe funding problems for the public health
insurance system.
Healthcare sector reform was initially a priority for the government,
replacing outmoded and impractical practices in place under the former
communist regime. A considerable number of healthcare institutions have been
renovated and a universal health insurance system implemented. The area of
primary care has seen a great deal of development; a consequence of neglect
under the pre-war regime. The government is now aiming to bring the
performance of the health sector into line with that of other EU member
states, through the National Health Strategy 2006-2011. The reform mainly
focuses on the healthcare delivery system, healthcare financing and public
health.
The pharmaceutical industry in Croatia is relatively small and is dominated by
local and regional generic suppliers. Croatia runs a negative balance of trade
in finished pharmaceuticals and a positive balance in raw materials. It is
also home to Pliva, one of the world' s largest generic manufacturers. Pliva
was acquired by the USA' s Barr Pharmaceuticals in October 2006.
Highly detailed report content
MARKET OUTLOOK
- Current market size
- Unique 5-year market projections
- Market outlook
- Market structure
- Including statistical data on imports and exports
- Market developments
- Recent and impending developments with respect to key issues such as
regulation, health facilities and government policy
- Key national data projections
BACKGROUND DATA
- Population data, including growth trends and age structure
- Demographic indicators detailing principal causes of death and morbidity
HEALTHCARE SYSTEM
- Health expenditure
- Expenditure by source of funding and type
- Hospital services
- Hospital data such as beds by type, specialty, patient admissions and
occupancy
- Outpatient care
- Medical personnel
- Data on healthcare professionals covering such areas as doctors by
specialty and dentists ACCESSING THE PHARMACEUTI
ACCESSING THE PHARMACEUTICAL MARKET
- Regulatory environment
- Patent protection & intellectual property rights
- Pricing & reimbursement
- Distribution channels
- Domestic production
Compelling reasons to buy this Espicom market report
Espicom is a leading provider of market and company information for business.
In addition to this analysis, Espicom provides detailed management reports on
over 60 established and emerging pharmaceutical markets around the world.
- Includes - FREE - three quarterly updated outlook reports on the
Croatian pharma market
- Unique and original market forecasts
- Insightful interpretation of market trends and developments
- Fantastic value - no-one else produces such quality data so cost
effectively
- Over 25 years continuous pharmaceutical market experience
- A team of full-time researchers and analysts
- Unbeatable access to primary sources
- Independent and impartial
- Formats to suit every distribution need and budget
View Cart
